Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Nov:132:104645.
doi: 10.1016/j.jcv.2020.104645. Epub 2020 Sep 16.

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay

Rahul Batra  1 , Luis Gonzalez Olivieri  2 , Delfin Rubin  3 , Ana Vallari  4 , Sandra Pearce  4 , Ana Olivo  4 , John Prostko  4 , Gaia Nebbia  1 , Sam Douthwaite  1 , Mary Rodgers  4 , Gavin Cloherty  4
Affiliations
Comparative Study

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay

Rahul Batra et al. J Clin Virol. 2020 Nov.

Abstract

Introduction: Antibodies to SARS-CoV-2 serve as critical diagnostic markers for determining how broadly the COVID-19 pandemic has spread, confirming patient recovery, monitoring potential long-term effects of infection, and evaluating potential protection from reinfection. As new antibody tests become available, it is important to evaluate their performance and utility. The aim of this study was to compare the performance of the Abbott PanbioTM COVID-19 IgG/IgM Rapid Test Device against the Abbott ArchitectTM SARS CoV-2 IgG Assay for the detection of the COVID-19 IgG antibody.

Methods: Two panels of specimens were utilized to challenge both antibody tests: (1) a set of 150 prepandemic negative specimens collected in 2014, and (2) a set of 122 specimens from 87 hospitalized COVID-19 patients in the US and UK that were confirmed with a positive SARS-CoV-2 RNA test result.

Results: The ArchitectTM test had a specificity of 100 % and sensitivity of 99.1 % and 93.9 % when excluding or including immunocompromised patients, respectively for specimens collected >14 days post symptom onset or >5 days post-RNA testing. The PanbioTM test had 99.3 % agreement to ArchitectTM. Notably, N = 6 immune-compromised individuals were identified that did not develop detectable antibodies by day 30.

Conclusion: There is good concordance between the ArchitectTM SARS CoV-2 IgG Assay and PanbioTM COVID-19 IgG/IgM Rapid Test Device for the detection of SARS CoV-2 IgG.

Keywords: Antibodies; COVID-19; Infection; SARS-CoV-2; Serology.

PubMed Disclaimer

Conflict of interest statement

Luis Gonzalez Olivieri, Mary Rodgers, Gavin Cloherty, Delfin Rubin, Ana Vallari, Sandra Pearce, Ana Olivo and John Prostko are employees and shareholders of Abbott Laboratories.

References

    1. WHO Coronavirus Disease (COVID-19) Dashboard: https://covid19.who.int/.
    1. Lou B., Li T., Zheng S., et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv. 2020 doi: 10.1101/2020.03.23.20041707. Preprint posted March 27. - DOI - PMC - PubMed
    1. Guo L., Ren L., Yang S., et al. Profiling early humoral response to diagnose novel coronavirus disease. Clin. Infect. Dis. 2020;(March (21)) doi: 10.1093/cid/ciaa310. - DOI - PMC - PubMed
    1. KK-W To, OT-Y Tsang, Leung W.-S., et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 2020;20(5):565–574. doi: 10.1016/S1473-3099(20)30196-1. - DOI - PMC - PubMed
    1. Long Q.-X., Liu B.-Z., Deng H.-J., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020 doi: 10.1038/s41591-020-0897-1. - DOI - PubMed

Publication types